Leena Watts
Fen-phen was a weight-loss drug that combined fenfluramine and phentermine. It was touted as a miracle cure for obesity and soared in popularity in the 1990s. However, it was later discovered that fen-phen could cause serious heart valve damage and pulmonary hypertension, leading to its removal from the market in 1997. The fallout from the fen-phen craze sparked discussion about the evaluation of drug safety and the role of the Food and Drug Administration (FDA) in approving and monitoring diet drugs.
| Characteristics | Values |
|---|---|
| Brand name | Fen-Phen |
| Generic name | Fenfluramine/phentermine |
| Drug class | Appetite suppressants |
| Drug type | Anti-obesity medication |
| Dosage form | Oral capsules |
| Administration | Once daily in the morning |
| Availability | No longer widely available |
| Side effects | Fast heart rate, high blood pressure, trouble sleeping, dizziness, restlessness, valvular heart disease, pulmonary hypertension |
| Manufacturer | Wyeth (formerly American Home Products) |
Explore related products
$11.97 $14.99
What You'll Learn
Fen-phen's popularity as a miracle weight-loss drug
Fen-phen, a combination of the drugs fenfluramine and phentermine, gained immense popularity in the early 1990s as a miracle weight-loss drug. While fenfluramine was first introduced in the 1970s to treat obesity, it did not gain much traction due to its temporary effects and uncomfortable side effects like nausea and anxiety.
In 1979, Dr. Michael Weintraub of the University of Rochester had the idea to combine fenfluramine with phentermine, a type of amphetamine. This combination was found to be more effective in treating obesity and avoiding the side effects of previous diet drugs. A 1984 study found that participants lost an average of 7.5 kg in 24 weeks, compared to 4.4 kg under a placebo.
Despite not being approved by the FDA, the combination drug fen-phen received a lot of media attention and was heavily marketed as a miracle weight-loss solution. It was prescribed by doctors and dispensed at weight-loss clinics, with some patients reporting that they received prescriptions after only very brief examinations.
However, concerns about the drug combination's safety began to emerge. In 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month and subsequently died in February 1997. This led to increased scrutiny and research into the potential side effects of fen-phen. A paper published in the New England Journal of Medicine in August 1997 reported a possible correlation between mitral valve dysfunction and the use of fen-phen. The FDA received additional reports of valvular heart disease and pulmonary hypertension, primarily in women who had taken the drug.
In September 1997, the FDA requested the withdrawal of fenfluramine and dexfenfluramine (a similar drug) from the market, citing the risk of heart valve defects in as many as a third of patients. This marked the end of fen-phen's popularity as a weight-loss drug.
Vegetarian Diet: Healthier, Happier, and More Sustainable
You may want to see also
Explore related products
Fen-phen's composition and mechanism of action
Fen-phen was a combination of two drugs: fenfluramine and phentermine. Fenfluramine was an appetite suppressant used to treat obesity. It was also a serotonergic medication, meaning it acted as a serotonin releasing agent. Phentermine, on the other hand, was a type of amphetamine that acted primarily as a norepinephrine-dopamine releasing agent. When combined, they created a well-balanced serotonin-norepinephrine releasing agent with weaker effects on dopamine release.
Fenfluramine was first introduced in the 1970s as a weight-loss drug but did not gain much traction as it only temporarily reduced weight. Phentermine, too, was approved for short-term use as a diet aid around the same time but was not very effective. In 1979, Dr. Michael Weintraub proposed combining the two drugs, which occurred in 1984. This combination was found to be much more effective for weight loss than either drug alone.
Fenfluramine and phentermine were never combined into a single pill. They were prescribed together and heavily marketed in the early 1990s as an anti-obesity medication. However, in 1997, the drug combination was withdrawn from the market due to concerns about potentially fatal pulmonary hypertension and heart valve problems.
The mechanism of action for fen-phen involved the regulation of serotonin and norepinephrine levels in the body. Fenfluramine acted on serotonin receptors, particularly the 5-HT2B receptors, which are plentiful in human cardiac valves. This action may have led to valvular abnormalities in patients. Phentermine, on the other hand, primarily increased the release of norepinephrine, which is involved in increasing metabolic rate and burning more calories.
Additionally, both drugs had effects on other neurotransmitters. Fenfluramine also stimulated the release of dopamine, although to a lesser extent than serotonin. Phentermine, being a type of amphetamine, also increased dopamine levels, as discovered by Wurtman during his experiments.
Nut Consumption on the 4-Hour Body Diet
You may want to see also
Explore related products
Fen-phen's side effects, including heart valve damage
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication that was sold in the early 1990s. It was a popular weight-loss treatment that gained rapid popularity. However, it was pulled from the market in 1997 after reports of serious side effects, including heart valve damage and pulmonary hypertension.
The first signs of trouble came in 1996 when a 30-year-old woman developed heart problems after taking fen-phen for just one month. She died in February 1997, and her story made the front page of the Boston Herald. Soon after, a paper in the New England Journal of Medicine from the Mayo Clinic discussed clinical findings in 24 people who had taken fen-phen. The authors noted a possible correlation between mitral valve dysfunction and the use of these anorectic agents.
The U.S. Food and Drug Administration (FDA) alerted medical practitioners and requested reports of similar cases. They subsequently received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. This prompted the FDA to request the withdrawal of fen-phen from the market in September 1997. The action was based on findings from doctors who had evaluated people taking these drugs with echocardiograms, which showed that approximately 30% of people who had taken the combination for up to 24 months had abnormal echocardiograms, despite showing no symptoms.
The side effects of fen-phen were not limited to heart valve damage and pulmonary hypertension. Fenfluramine was shown to cause potentially fatal pulmonary hypertension and heart valve problems, which led to its withdrawal from the market. Phentermine, on the other hand, has side effects such as a fast heart rate, high blood pressure, trouble sleeping, dizziness, and restlessness.
The fallout from the fen-phen disaster was significant, with more than 50,000 product liability lawsuits filed by alleged victims and total liability estimated to be as high as $14 billion. Wyeth, the company that marketed fen-phen, set aside $21.1 billion to cover the cost of lawsuits and offered settlements ranging from $5,000 to $200,000 to injured parties.
Bacon: A FODMAP Diet-Friendly Food
You may want to see also
Explore related products
Fen-phen's removal from the market by the FDA
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication that gained rapid popularity in the early 1990s. Despite not being approved by the FDA, it was heavily marketed as a "miracle" weight-loss drug. However, in 1997, concerns emerged about its safety, leading to its withdrawal from the market.
The drug combination was first introduced in the 1970s, but it was not well-received due to temporary weight loss and side effects like nausea and anxiety. In the 1990s, fenfluramine was combined with phentermine, and this combination was touted as a more effective treatment for obesity without the annoying side effects of previous diet drugs. This sparked immense popularity, and it was even used to treat severe obesity and some drug and alcohol addictions.
However, in 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month and subsequently died in February 1997. This tragedy sparked concerns about the safety of the drug combination. In August 1997, a paper in the New England Journal of Medicine reported clinical findings in 24 people who had taken fen-phen, suggesting a possible link between mitral valve dysfunction and the use of these anorectic agents. The FDA received additional reports of valvular heart disease and pulmonary hypertension, primarily in women who had been treated with fen-phen or dexfenfluramine.
In response to these alarming reports, the FDA requested the withdrawal of fenfluramine and dexfenfluramine from the market in September 1997. The decision was based on findings from doctors who evaluated people taking these drugs with echocardiograms, revealing that approximately 30% of people who had taken the combination for up to 24 months had abnormal echocardiograms, despite being asymptomatic. This rate of abnormal results was significantly higher than expected, indicating an unacceptable risk to patients.
The removal of fen-phen from the market by the FDA marked a turning point in the understanding of the potential dangers of weight-loss drugs. It highlighted the importance of long-term benefit assessments beyond modest short-term weight loss. The aftermath saw a wave of litigation, with over 50,000 product liability lawsuits filed and total liability estimated at $14 billion.
Cottage Cheese on Atkins: Healthy or Not?
You may want to see also
Explore related products
Lawsuits and settlements related to fen-phen
Fen-phen was a popular diet pill combination of fenfluramine and phentermine. Fenfluramine was marketed as Pondimin and Redux, while phentermine was the "phen" in fen-phen. In 1996, doctors wrote a collective 18 million prescriptions for the two drugs. However, in 1997, the drugs were removed from the market at the request of the Food and Drug Administration (FDA) after studies linked them to heart valve damage and lung problems.
Since the recall was first announced in 1997, thousands of lawsuits have been filed against the manufacturers of fen-phen, with plaintiffs alleging that they had failed to adequately warn physicians and consumers of the risks associated with the drugs. In 1999, American Home Products Corp agreed to pay $3.75 billion in total to thousands of people who claimed they were injured by taking fen-phen. The settlement, one of the largest ever in product liability cases, did not shield American Home Products from all fen-phen liabilities, and the company could still be liable for higher payouts.
In August 2000, the Court approved a $4.75 billion settlement offering medical monitoring relief for persons exposed to the diet drugs. Additionally, in 2023, BrownGreer was named Claim Administrator for the $5 billion settlement trust for more than 700,000 claimants in the national class action settlement of "Fen-Phen" diet drug claims.
Qualifying Pondimin and Redux users who have already received Matrix Compensation from the Original AHP Settlement may file a supplemental claim if their condition worsens. As of 2021, Fen-Phen Lawyer, Cynthia K. Garrett, has been representing Pondimin and Redux victims since 1998 and is accepting new Fen-Phen clients nationwide.
Grapes and Loaf Potassium Diets: What's Allowed?
You may want to see also
Frequently asked questions
Fen-Phen was a combination of fenfluramine and phentermine, a "miracle" weight-loss drug.
In 1997, thousands of people suffered serious heart and/or lung damage after taking the drug.
The FDA received information on 113 cases, in addition to the original 24 publicly reported cases. This led to the drug being withdrawn from the market.
Fen-Phen caused Pulmonary Hypertension (PH), which is high blood pressure in the lungs. It also caused cardiac-valve regurgitation and heart valve damage.
Yes, thousands of lawsuits were filed against American Home Products (later known as Wyeth) for cardiovascular injuries. In 2000, a settlement of $4.75 billion was approved to cover medical monitoring and patient compensation.
